Standard-of-care treatments for patients with recurrent glioblastoma are not well defined; treatment is selected on the basis of prior therapy, age, KPS, MGMT promoter methylation status and patterns of disease progression (Fig. 3). This evidence concerns the gene MGMT and glioblastoma.